Towards antivirals against chikungunya virus.

Abstract

Chikungunya virus (CHIKV) has re-emerged in recent decades, causing major outbreaks of chikungunya fever in many parts of Africa and Asia, and since the end of 2013 also in Central and South America. Infections are usually associated with a low mortality rate, but can proceed into a painful chronic stage, during which patients may suffer from polyarthralgia and joint stiffness for weeks and even several years. There are no vaccines or antiviral drugs available for the prevention or treatment of CHIKV infections. Current therapy therefore consists solely of the administration of analgesics, antipyretics and anti-inflammatory agents to relieve symptoms. We here review molecules that have been reported to inhibit CHIKV replication, either as direct-acting antivirals, host-targeting drugs or those that act via a yet unknown mechanism. This article forms part of a symposium in Antiviral Research on "Chikungunya discovers the New World."

• Authors: Rana Abdelnabi, Johan Neyts, Leen Delang
• Journal: Antiviral research (Antiviral Res) Vol. 121 Pg. 59-68 (Sep 2015) ISSN: 1872-9096 [Electronic] Netherlands
• PMID: 26119058 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2015 Elsevier B.V. All rights reserved.

Chemical References

• Antiviral Agents

Topics

• Animals
• Antiviral Agents (isolation & purification, pharmacology)
• Chikungunya virus (drug effects)
• Drug Discovery (trends)
• Humans